Alnylam Pharmaceuticals Inc. Common Stock (ALNY)
Stock · NASDAQ · Health Care
$237.1as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Resistance level
$316.85
Industry
Biotechnology: Pharmaceutical Preparations
Alnylam Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$237.1▲ 0.23%Market cap $29.48BP/E —
- ZTSZoetis Inc. Class A Common Stock$77.36▲ 3.12%Market cap $32.32BP/E 11.54$71$156.49
- ONCBeOne Medicines Ltd. American Depositary Shares$366.79▼ 1.53%Market cap $34.88BP/E 88.12$205.51$346
- ROIVRoivant Sciences Ltd. Common Shares$34.71▼ 7.64%Market cap $24.08BP/E —$11.85$37.97
- UTHRUnited Therapeutics Corporation Common Stock$515.57▼ 2.34%Market cap $21.92BP/E 17.03$302.19$609.35
- INSMInsmed Incorporated Common Stock$118.52▼ 2.36%Market cap $21.34BP/E —$90.39$212.75
- VTRSViatris Inc. Common Stock$16.34▼ 3.26%Market cap $20.53BP/E —$9.43$18.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $29.48B | — | $237.1 | ▲ 0.23% | |
| ZTS Zoetis Inc. Class A Common Stock | $32.32B | 11.54 | $77.36 | ▲ 3.12% | $71$156.49 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $34.88B | 88.12 | $366.79 | ▼ 1.53% | $205.51$346 |
| ROIV Roivant Sciences Ltd. Common Shares | $24.08B | — | $34.71 | ▼ 7.64% | $11.85$37.97 |
| UTHR United Therapeutics Corporation Common Stock | $21.92B | 17.03 | $515.57 | ▼ 2.34% | $302.19$609.35 |
| INSM Insmed Incorporated Common Stock | $21.34B | — | $118.52 | ▼ 2.36% | $90.39$212.75 |
| VTRS Viatris Inc. Common Stock | $20.53B | — | $16.34 | ▼ 3.26% | $9.43$18.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 116.38M
- Total value held
- $36.02B
- Institutional holders
- 776
Top holders this quarter
- Unknown14.58M
- Unknown10.80M
- Unknown10.44M
- Unknown9.47M
- Unknown5.95M
- Unknown5.19M
- Unknown3.32M
- Unknown2.66M
- Unknown2.49M
- Unknown1.99M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 28, 2026
Alnylam to Present Transthyretin Amyloidosis Data at ESC Congress 2026. Alnylam Pharmaceuticals announced it will present new clinical and real-world data at ESC Congress 2026, a major cardiology conference. The presentations will cover transthyretin-mediated amyloidosis and hypertension programs, key areas of the company's research pipeline. Sharing findings at major medical conferences allows companies to engage with the scientific community and healthcare professionals. The stock is currently trading near technical support around $317 with an RSI of 47, indicating neither overbought nor oversold conditions.